Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Bernstein's top two SMID biotech picks for 2025
January 8, 2025 6:00 PM ESTBernstein analysts identified Biohaven Pharma (NYSE: BHVN) and Beam Therapeutics Inc. (NASDAQ: BEAM) as their top small- to mid-cap (SMID) biotech picks for 2025, citing promising developments in their respective platforms.
Bernstein expresses "high conviction" in Biohavens degrader platform, with an update expected in the first quarter of 2025.
They highlight... More



